Is It Really All about the Money? Reconsidering Non-Financial Interests in Medical Research

Journal of Law, Medicine and Ethics

Volumn 40, Issue 3, 2012, Pages 467-481

  Saver, Richard S ^a  

^a IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPETITIVE BEHAVIOR; CONFLICT OF INTEREST; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HUMAN; LEGAL ASPECT; MEDICAL RESEARCH; MOTIVATION; POLICY; SOCIAL BEHAVIOR; UNITED STATES;

BIOMEDICAL RESEARCH; COMPETITIVE BEHAVIOR; CONFLICT OF INTEREST; HUMANS; MOTIVATION; PUBLIC POLICY; RESEARCH SUPPORT AS TOPIC; SOCIAL BEHAVIOR; UNITED STATES;

EID: 84867624571     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2012.00679.x     Document Type: Article

References (87)

1. Department of Health and Human Services, "Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors, " 76 Federal Register 53256 (August 25, 2011).
2. Institute of Medicine, Conflict of Interest in Medical Research, Education, and Practice ( Washington, D.C. : National Academies Press, 2009) (hereinafter cited as IOM, Conflict of Interest Report).
3. Washington University School of Medicine Conflicts of Interest Policy Part I, §B.3, Part II, §D.1 (while the University's conflict of interest policy acknowledges that faculty and staff face many forms of competing interests, the Disclosure Review Committee addresses only financial conflicts), available at (last visited July 24, 2012);
4. Mayo Clinic Conflict of Interest Policy §§I, II (recognizing that "conflict of interest" encompasses financial or other personal considerations but then defining conflicts of interest for purposes of institutional policy as situations where there may have been influence by "significant financial conflict of interest"), available at (last visited July 24, 2012);
5. Report of the AAMC-AAU Advisory Committee on Financial Conflicts of Interest in Human Subjects Research, Protecting Patients, Preserving Integrity, Advancing Health: Accelerating the Implementation of COI Policies in Human Subjects Research (2008) (concentrating exclusively on financial conflicts);
6. J. A. Blum et al., "Requirements and Definitions in Conflict of Interest Policies of Medical Journals, " JAMA 302, no. 20 (2009): 2230-2234 (most medical journals surveyed requested author disclosure of financial conflicts but only a minority requested disclosure of other potential conflicts such as personal relationships).
7. The IRB regulations restrict IRB members with conflicting interests from participating in protocol reviews, but the rules do not specify what types of interests trigger the restrictions. See 45 C.F.R. §46.107(e); 21 C.F.R. § 56.107 (e). IRBs apply the rules more often to financial conflicts than non-financial interests. See L.E. Wolf et al., "Conflicts of Interest in Research: How IRBs Address Their Own Conflicts, "IRB: Ethics and Human Research 29, no. 1 (2007): 6-12 (70% of surveyed IRBs interpret conflict of interest for an IRB member as covering financial ties, but only 52% consider some relationships with study personnel to be a conflict). Among IRBs that consider non-financial ties, not all potentially conflicting relationships are consistently included.
8. H. Brody, "Clarifying Conflict of Interest, " American Journal of Bioethics 11, no. 1 (2011): 23-28.
9. "Following the Money, "American Journal of Law and Medicine 36 (2010): 288-481 (symposium issue addressing the core theme of following the money in health care).
10. L. Shepherd et al., "In Plain Sight: A Simple Solution to a Fundamental Challenge in Human Research, " Journal of Law, Medicine and Ethics (forthcoming 2012); IOM, Conflict of Interest Report, supra note 3, at 97.
11. G. DuVal, "Institutional Conflicts of Interest: Protecting Human Subjects, Scientific Integrity, and Institutional Accountability, " Journal of Law, Medicine & Ethics 32, no. 4 (2004): 613-625.
12. S. Sollitto et al., "Intrinsic Conflicts of Interest in Clinical Research: A Need for Disclosure, " Kennedy Institute of Ethics Journal 13, no. 2 (2003): 83-91.
13. J. P. Kassirer et al., "Financial Conflicts of Interest in Biomedical Research, " New England Journal of Medicine 329, no. 8 (1993): 570-571.
14. W. Sage, "Some Principles Require Principals: Why Banning 'Conflicts of Interest' Won't Solve Incentive Problems in Biomedical Research, " Texas Law Review 85 (2007): 1413-1463.
15. S. Fry-Revere et al., "More Regulation of Industry Supported Biomedical Research: Are We Asking the Right Questions?" Journal of Law, Medicine & Ethics 37, no. 3 (2009): 420-430.
16. N. G. Levinsky, "Nonfinancial Conflicts of Interest in Research, " New England. Journal of Medicine 347, no. 10 (2002): 759-761;
17. P. J. Harrington, "Faculty Conflicts of Interest in an Age of Academic Entrepreneurialism: An Analysis of the Problem, the Law and Selected University Policies, " Journal of College and University Law 27, no. 4 (2001): 775-831.
18. The PLoS Medicine Editors, "Making Sense of Non-Financial Competing Interests, " PLoS Medicine 5, no. 9 (2008): 1299-1301; International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest, available at (last visited July 24, 2012).
19. L. E. Wolf et al., "Ethical Issues in Clinical Research: An Issue for All Internists, " American Journal of Medicine 109, no. 1 (2000): 82-85;
20. M. B. Cope et al., "White Hat Bias: A Threat To The Integrity of Scientific Reporting, " Acta Paediatrica 99, no. 11 (2010): 1615-1617.
21. D. Korn, "Conflicts of interest in Biomedical Research, " JAMA 284, no. 17 (2000): 2234-2237.
22. P. C. Kuszler, "Curing Conflicts of Interest in Clinical Research: Impossible Dreams and Harsh Realities, " Widener Law Symposium Journal 8 (2001): 115-152
23. Institute of Medicine, Responsible Research: A Systems Approach to Protecting Research Participants (Washington, D.C.: The National Academies Press, 2002) (hereinafter cited as IOM, Responsible Research): at 187.
24. In the federally sponsored Tuskegee Syphilis Study, poor African-American men suffering from syphilis were deliberately left untreated as part of an investigation of the natural history of the disease. The subjects were not aware that they were in the study and several were not even told that they had syphilis. See generally J. Jones, Bad Blood: The Tuskegee Syphilis Experiment - A Tragedy of Race and Medicine (New York: The Free Press, 1981).
25. Live cancer cells were injected into elderly patients at the Jewish Chronic Disease Hospital in Brooklyn without the patients' knowledge or consent. The study, funded in part by the United States Public Health Service and American Cancer Society, investigated how a weakened immune system influenced the spread of cancer. See Hyman v. Jewish Chronic Disease Hospital, 251 N.Y.S.2d 818 (N.Y. App. Div. 1964); T. W. Rice, "The Historical, Ethical, and Legal Background of Human Subjects Research, " Respiratory Care 53, no. 10 (2008): 1325-1329.
26. National Research Act of 1974, Pub. L. No. 93-348 (1974), 88 Stat. 342. The Act required that institutions receiving Department of Health, Education, and Welfare funding for research studies establish institutional review boards in order to protect subjects. It also authorized creation of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.
27. In 1981, the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) substantially revised their regulations, implementing various provisions of the National Research Act of 1974, see id., and recommendations of the Belmont Report issued by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. See National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (1978). The 1981 research rules have remained largely unchanged to present day, although HHS and FDA are considering more comprehensive changes to the regulations. See Department of Health and Human Services and the Food and Drug Administration, "Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, " 76 Federal Register 44512 (July 26, 2011) (Advanced notice of proposed rulemaking).
28. P. N. Ossorio, "Pills, Bills, and Shills: Physician-Researcher's Conflicts of Interest, "Widener Law Symposium Journal 8, no.1 (2001): 75-103.
29. M. B. Landon et al., "A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes, " New England Journal of Medicine. 361, no. 14 (2009): 1339-1348.
30. L. K. Stell, "Conflict of Interest in Diabetes Research, " Journal of Diabetes 2, no. 1 (2010): 5-6, at 5 ("imagine the outcry were similar excess harm to an at-risk population of pregnant women and infants allowed to accumulate in an industry-sponsored trial where its physician-investigators held equity interests in the outcome.").
31. B. Werth, "The Drug That Works in Pittsburgh, " New York Times, September 30, 1990.
32. generally World Health Organization, Evidence on The Long-Term Effects of Breastfeeding: Systematic Reviews and Meta-Analyses (WHO Press, Geneva: 2007); R. L. Atkinson et al., "White Hat Bias: The Need for Authors to Have the Spin Stop with Them, " International Journal of Obesity 34, no. 1 (2010): 83.
33. L. L. Kjaergard et al., "Association Between Competing Interests and Authors' Conclusions: Epidemiological Study of Randomised Clinical Trials Published in the BMJ, " British Medical Journal 325, no. 7358 (2002): 1-4.
34. L. Luborsky et al., "The Researcher's Own Therapy Allegiances: A 'Wild Card' In Comparisons of Treatment Efficacy, " Clinical Psychology: Science and Practice 6, no. 1 (1999): 95-106
35. M. Maj, "Non-Financial Conflicts of Interest in Psychiatric Research and Practice, " The British Journal of Psychiatry 193, no. 2(2008): 91-92
36. J. Menikoff and E. Richards, What the Doctor Didn't Say: The Hidden Truth about Medical Research ( New York : Oxford University Press, 2006): at 226.
37. Sharmon Sollitto and colleagues assert that "intrinsic conflicts of interest pose as grave a problem as overt personal financial conflicts". Sollitto, supra note 10, at 85 (2003). See also D.F. Horrobin, "Non-Financial Conflicts Are More Serious Than Financial Conflicts, "British Medical Journal 318, no.7181 (1999): 466 ("non-financial conflicts are much more serious barriers to the fair conduct, reporting, and criticism of research studies.").
38. G. Guyatt et al., "The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution, " Annals Internal Medicine 152, no. 11 (2010): 738-741.
39. A. C. Tsai, "Managing Nonfinancial Conflicts of Interest: How the New McCarthyism Could Work, " American Journal of Bioethics 11, no. 1 (2011): 42-44, at 42-43.
40. E. A. Boyd, "Defining Financial Conflicts and Managing Research Relationships: An Analysis of University Conflict of Interest Committee Decisions, " Science and Engineering Ethics 13, no. 4 (2007): 415-435.
41. T. S. Huddle, "Clarifying the Dispute over Academic-Industry Relationships, " American Journal of Bioethics 11, no. 1 (2011): 47-49.
42. R. Horton, "Conflicts of Interest in Clinical Research: Opprobrium or Obsession?" The Lancet 349, no. 9059 (1997): 1112-1113.
43. C. Robertson, "Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence, " Journal of Law, Medicine & Ethics 40, no. 3 (2012): 502-516.
44. T. D. Warner et al. "What Do We Really Know about Conflicts of Interest in Biomedical Research?", Psychopharmacology 171, no. 1 (2003): 36-46.
45. R. Bailey, Scrutinzing Industry-Funded Science: The Crusade against Conflicts of Interest ( New York : American Council on Science and Health, 2008), available at (last visited August 19, 2012).
46. T. P. Stossel, "Regulating Academic-Industrial Research Relationships - Solving Problems or Stifling Progress?" New England Journal of Medicine 353, no. 10 (2005): 1060-1065.
47. J. Johnston, "Financial Conflicts of Interest in Biomedical Research, " in Trust and Integrity in Biomedical Research (The Johns Hopkins University Press, Baltimore : 2010): at 16. As even the IOM 2009 Conflict of Interest Report concedes, "on many topics related to conflicts of interest, no systematic studies are available ... [while] for other topics, data are suggestive rather than definitive". IOM, Conflict of Interest Report, supra note 3, at 4.
48. Remarks of Marcia Angell, HHS Conference on Financial Conflicts of Interest, August 16, 2000, available at (last visited July 24, 2012).
49. N. J. Kachuck, "Managing Conflicts of Interest and Commitment: Academic Medicine and the Physician's Progress, " Journal of Medical Ethics 37, no. 1 (2011): 2-5, at 4.
50. D. K. Nelson, "Conflict of Interest: Researchers, " in R. Amdur and E. Bankert, Institutional Review Board: Management and Function ( Sudbury, MA : Jones and Bartlett Publishers, 2002): 197-203, at 198.
51. The Center for Health and Pharmaceutical Law and Policy, Seton Hall University School of Law, The Limits of Disclosure as a Response to Financial Conflicts of Interest in Clinical Research (2010), available at .
52. Department of Health and Human Services, Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors, 76 Federal Register 53256, 53258 (August 25, 2011) (implementing final rule). HHS also justified the exclusive focus on financial ties because the authorizing legislation for the regulations expressly references financial conflicts.
53. T. A. Brennan et al., "Health Industry Practices That Create Conflicts of Interest, " JAMA 295, no. 4 (2006): 429-433;
54. J. Dana, "How Psychological Research Can Inform Policies for Dealing with Conflicts of Interest in Medicine, " in IOM Conflict of Interest Report, Appendix D, supra note 3, at 370.
55. D. Katz et al., "All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving, " American Journal of Bioethics 3, no. 3 (2003): 39-46;
56. Association of American Medical Colleges et al., The Scientific Basis of Influence and Reciprocity: A Symposium (Washington, D.C.: 2007), available at (last visited August 10, 2012);
57. J. Dana, et al. "A Social Science Perspective on Gifts to Physicians From Industry, ", JAMA 290, no. 2, (2003): 252-255.
58. S. A. Magnus, "Physicians' Financial Incentives in Five Dimensions: A Conceptual Framework for HMO Managers, " Health Care Management Review 24, no. 1 (1999): 57-72;
59. R. S. Saver, "Squandering the Gain; Gainsharing and the Continuing Dilemma of Physician Financial Incentives, " Northwestern University Law Review 98, no. 1 (2003): 145-238.
60. S. Fry-Revere et al., "More Regulation of Industry Supported Biomedical Research: Are We Asking the Right Questions?" Journal of Law, Medicine & Ethics 37, no. 3 (2009): 420-430.
61. R. Bailey, "Ties that Bind: The Canonical Conflict of Interest Cases, " Reason, October 2007, available at (last visited July 24, 2012) ("One of the often-expressed concerns about conflicts of interest is that greedy researchers will harm subjects and patients as they rush treatments to market. [The Gelsinger] case stands out in this respect.").
62. S. G. Stolberg, "The Biotech Death of Jesse Gelsinger, " New York Times Magazine, November 28, 1999, at 136;
63. J. A. Goldner, "Dealing with Conflicts of Interest in Biomedical Research: IRB Oversight as the Next Best Solution to the Abolitionist Approach, " Journal of Law, Medicine & Ethics 28, no. 4 (2000): 379-404.
64. R. F. Wilson, "Estate of Gelsinger v. Trustees of University of Pennsylvania: Money, Prestige, and Conflicts of Interest in Human Subjects Research, " in S. Johnson et al., eds., Health Law and Bioethics: Cases in Context ( New York : Aspen Publishers, 2009): at 229-231.
65. L. A. Alvino, "Who's Watching the Watchdogs? Responding to the Erosion of Research Ethics by Enforcing Promises, " Columbia Law Review 103 (2003): 893-923, ("Although the news stories written immediately after Jesse Gelsinger's death portrayed the experiment as a noble endeavor with a tragic outcome, that tone was soon replaced with one of anger and general distrust of the medical research community, as evidence of apparent financial conflicts of interest and breaches of protocol eventually emerged.").
66. D. Nelson and R. Weiss, "Hasty Decision in the Race to a Cure? Gene Therapy Study Proceeded Despite Safety, Ethics Concerns, " Washington Post, November 21, 1999.
67. J. M. Wilson, "Lessons Learned From the Gene Therapy Trial For Ornithine Transcarbamylase Deficiency, " Molecular Genetics and Metabolism 96, no. 4 (2009): 151-157.
68. ("[I]t seems unlikely that administrators at one of the nation's most prestigious institutions, who regularly deal with amounts in the many millions of dollars, would have been pressuring researchers to cut corners because of the possibility that Penn's rather modest share of the company ($1.4 million) would then be worth more.").
69. R. Steinbrook, "The Gelsinger Case, " in the Oxford Textbook of Clinical Research Ethics ( Oxford : New York, 2008): 110-120, at 118.
70. Department of Health and Human Services, Financial Relationships and Interests in Research involving Human Subjects: Guidance for Human Subject Protection, 69 Federal Register 26393 (2004).
71. R. B. Cialdini, Influence: The Psychology of Persuasion, 2nd ed. ( New York : Quill, 1993): at 18.
72. Katz, supra note 66; D. Blumenthal, "Doctors and Drug Companies, " New England Journal of Medicine 351, no. 18 (2004): 1885-1890.
73. S. Gray et al., "Attitudes Toward Research Participation and Investigator Conflicts of Interest Among Advanced Cancer Patients Participating in Early Phase Clinical Trials, " Journal of Clinical Oncology 25, no. 23 (2007): 3488-3494.
74. L. Hampson et al., "Patients' Views on Financial Conflicts of Interest in Cancer Research Trials, " New England Journal of Medicine 355, no. 22 (2006): 2330-2337.
75. C. Grady et al., "The Limits of Disclosure: What Research Subjects Want to Know About Investigator Financial Interests, " Journal Law, Medicine & Ethics 34, no. 23 (2006): 592-599;
76. K. Weinfurt, et al. "Effects of Disclosing Financial Interests on Attitudes toward Clinical Research, ", Journal of General Internal Medicine 23, no. 6: 860-866.
77. B. Williams-Jones, "Beyond a Pejorative Understanding of Conflict of Interest, " American Journal of Bioethics 11, no. 1 (2011): 1-2.
78. R. A. Guzzo and R. A. Katzell, "Effects of Economic Incentives on Productivity, " in Incentives, Cooperation, and Risk Sharing ( Totowa, New Jersey : Rowman and Littlefield: 1987): 107-119, at 109.
79. National Bioethics Advisory Commission, Ethical and Policy Issues In Research Involving Human Participants, Bethesda, MD, 2001, at 64
80. R. S. Saver, "Medical Research Oversight from the Corporate Governance Perspective: Comparing Institutional Review Boards and Corporate Boards, " William and Mary Law Review 46, no. 2 (2004): 619-730, at 699-705.
81. C. I. Jackson, et al., "Honor in Science, "American Scientist 71, no. 5 (1983): 462-464.
82. Along these lines, recent changes to the standard NIH grant application, made as part of the agency's enhancing peer review process, limit the applicant to listing 15 previously published studies, in an effort to reward for quality over quantity. See generally National Institutes of Health, Details of Application Changes for Research Grants and Cooperative Agreements available at (last visited July 24, 2012).
83. A. S. Kesselheim et al., "Managing Financial and Nonfinancial Conflicts of Interest in Healthcare Delivery, " American Journal of Therapeutics 17, no. 4 (2010): 440-443;
84. C. M. Ulrich, et al., "Respondent Burden in Clinical Research: When Are We Asking Too Much of Subjects?" IRB: Ethics and Human Research 27, no. 4 (2005): 17-20, at 19.
85. International Committee of Medical Journal Editors, Form For Disclosure Of Potential Conflicts of Interest, Part 4, available at (last visited July 24, 2012).
86. C. Sunstein, "On the Expressive Function of Law, " University of Pennsylvania Law Review 144 (1996): 2021-2053
87. M. Hall, "Law, Medicine, and Trust, " Stanford Law Review 55, no. 2 (2002): 463-526.